NCT04655599 is a Phase 1 clinical trial of Olorinab in Irritable Bowel Syndrome, sponsored by Arena Pharmaceuticals.

Who is sponsoring NCT04655599?

NCT04655599 is sponsored by Arena Pharmaceuticals.

What drugs are being tested in NCT04655599?

Interventions in NCT04655599: Olorinab, Placebo.

What condition does NCT04655599 study?

NCT04655599 studies Irritable Bowel Syndrome.

Is NCT04655599 still recruiting?

NCT04655599 is currently terminated. Last updated 17 May 2021.

Last reviewed 2021-05-17 · How we verify

NCT04655599

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Terminated Phase 1 Last updated 17 May 2021

What this trial tests

Phase 1 trial testing Olorinab in Irritable Bowel Syndrome in 1 participant. Terminated before completion.

Timeline

29 January 2021

Primary endpoint
13 April 2021

13 April 2021

Quick facts

Lead sponsor	Arena Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	1
Start date	29 January 2021
Primary completion	13 April 2021
Estimated completion	13 April 2021
Sites	1 location across United States

Drugs / interventions tested

Olorinab — full drug profile →
Placebo

Conditions studied

Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →

Sponsor

Arena Pharmaceuticals — full company profile →

Who can join

Adults 18 to 70, any sex, with Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in adult participants with irritable bowel syndrome (IBS).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.
Singh R, Zogg H, Ghoshal UC, Ro S. · · 2022 · cited 67× · PMID 35145413 · DOI 10.3389/fphar.2022.808195
The Impact of the CB<sub>2</sub> Cannabinoid Receptor in Inflammatory Diseases: An Update.
Rakotoarivelo V, Mayer TZ, Simard M, Flamand N, et al · · 2024 · cited 34× · PMID 39064959 · DOI 10.3390/molecules29143381
Molecular mechanisms of pain in acute pancreatitis: recent basic research advances and therapeutic implications.
Wu Y, Han C, Luo R, Cai W, et al · · 2023 · cited 9× · PMID 38188196 · DOI 10.3389/fnmol.2023.1331438

Verify or expand the search:

Other trials of Olorinab

Trials testing the same drug.

NCT04043455 — Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant · Phase 2 · terminated
NCT03155945 — Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain · Phase 2 · completed

Other recruiting trials for Irritable Bowel Syndrome

Currently open trials in the same condition.

NCT07235228 — Effects of Vivatlac Synbiotic on Gut Micribiota of IBS Patients · NA · recruiting
NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07484412 — Efficacy and Safety of Encapsulated Bifidobacterium Longum BBH016 in Subjects With Lower Gastrointestinal Symptoms · NA · active not recruiting

Other Arena Pharmaceuticals trials

Trials by the same sponsor.

NCT03996369 — Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 3 · completed
NCT04162769 — A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis · Phase 2 · completed
NCT04043455 — Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant · Phase 2 · terminated
NCT03945188 — Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis · Phase 3 · completed
NCT03155932 — Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04655599 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arena Pharmaceuticals
Last refreshed: 17 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04655599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing